基于专利法与竞争法交叉视角下的制药产业专利常青策略  

Evergreening of Patent in Pharmaceutical Industry:Crossroad between Patent Law and Competition Law

作　　者：赵歆[1] 刘晓海[1] 

机构地区：[1]同济大学法学院,上海200092

出　　处：《中国科技论坛》2014年第11期81-85,共5页Forum on Science and Technology in China

基　　金：国家社科基金项目"促进自主创新能力建设的国家知识产权政策体系研究"(12&ZD073);国家知识产权局专利保护重点联系机制工作项目(20121029952)

摘　　要：原研药企对原始专利修改并策略性提交专利申请的专利常青行为日益引起关注,这种对专利权滥用的行为究竟应通过专利法的内在矫正实现自我完善,还是通过竞争法的外在介入予以规制在各国有不同看法。本文对印度、美国、欧盟及加拿大规制专利常青行为予以介绍,得出结论,即应在我国还未明显出现专利常青现象时就采取预防措施,考虑制药产业收回研发成本和关乎公共卫生的属性而采取宽严适度的药品可专利性标准,并审慎将竞争法用于专利常青。The evergreening of patent in pharmaceutical industry, which refers to different ways to extend original patents, has increasingly drawn attention worldwide. To solve the problem, a key point is whether relying on the reform of patent law or applying competition law. This paper analyzes different attitudes in India, the U. S. , EU and Canada, and finally concludes that given the unique nature of pharmaceutical industry, the patentability criterion should be appropriately applied and competition law should be applied in a manner that differs from the way it is applied to companies in other sectors.

关 键 词：专利常青 制药产业 专利法 竞争法 

分 类 号：D923.4[政治法律—民商法学]